GW&K Investment Management LLC Lowers Holdings in ICU Medical, Incorporated (NASDAQ:ICUI)

GW&K Investment Management LLC decreased its stake in ICU Medical, Incorporated (NASDAQ:ICUI) by 12.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 347,480 shares of the medical instruments supplier’s stock after selling 48,596 shares during the quarter. ICU Medical makes up 0.8% of GW&K Investment Management LLC’s holdings, making the stock its 25th largest position. GW&K Investment Management LLC’s holdings in ICU Medical were worth $55,457,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its position in ICU Medical by 22.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,478,883 shares of the medical instruments supplier’s stock worth $876,365,000 after purchasing an additional 640,425 shares in the last quarter. Janus Henderson Group PLC boosted its position in ICU Medical by 5.2% during the second quarter. Janus Henderson Group PLC now owns 2,825,836 shares of the medical instruments supplier’s stock worth $711,856,000 after purchasing an additional 140,123 shares in the last quarter. BlackRock Inc. boosted its position in ICU Medical by 4.9% during the second quarter. BlackRock Inc. now owns 1,558,317 shares of the medical instruments supplier’s stock worth $392,555,000 after purchasing an additional 72,346 shares in the last quarter. JPMorgan Chase & Co. boosted its position in ICU Medical by 4.2% during the second quarter. JPMorgan Chase & Co. now owns 539,633 shares of the medical instruments supplier’s stock worth $133,867,000 after purchasing an additional 21,930 shares in the last quarter. Finally, Invesco Ltd. boosted its position in ICU Medical by 28.1% during the second quarter. Invesco Ltd. now owns 428,233 shares of the medical instruments supplier’s stock worth $107,876,000 after purchasing an additional 93,904 shares in the last quarter. Institutional investors own 93.60% of the company’s stock.

In other news, Director Robert S. Swinney sold 2,078 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $165.18, for a total transaction of $343,244.04. Following the completion of the transaction, the director now directly owns 17,345 shares in the company, valued at $2,865,047.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Robert S. Swinney sold 373 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $153.49, for a total value of $57,251.77. Following the transaction, the director now owns 18,845 shares of the company’s stock, valued at $2,892,519.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,451 shares of company stock valued at $862,736. Company insiders own 11.40% of the company’s stock.

A number of equities analysts have issued reports on the company. BidaskClub upgraded ICU Medical from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Zacks Investment Research downgraded ICU Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. ValuEngine upgraded ICU Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. TheStreet downgraded ICU Medical from a “b-” rating to a “c+” rating in a research report on Monday, August 12th. Finally, Raymond James set a $185.00 target price on ICU Medical and gave the company a “buy” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $233.00.

Shares of NASDAQ ICUI traded up $1.50 during midday trading on Friday, hitting $167.21. The stock had a trading volume of 101,800 shares, compared to its average volume of 198,185. ICU Medical, Incorporated has a 1 year low of $148.89 and a 1 year high of $259.72. The stock has a 50 day simple moving average of $158.57 and a 200-day simple moving average of $202.51. The company has a market capitalization of $3.46 billion, a PE ratio of 21.69 and a beta of 0.91.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.86 by $0.13. ICU Medical had a return on equity of 12.41% and a net margin of 3.56%. The business had revenue of $312.30 million during the quarter, compared to analyst estimates of $315.47 million. During the same period last year, the business posted $2.69 earnings per share. The company’s quarterly revenue was down 13.4% on a year-over-year basis. Equities research analysts anticipate that ICU Medical, Incorporated will post 7.21 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Article: Trading Penny Stocks

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Incorporated (NASDAQ:ICUI).

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit